Product Description
Drug candidate IRL757 originate from the P001 research program and aims to improve apathy in patients with Parkinson and other neurological diseases. (Sourced from: https://irlab.se/project-portfolio/irl757/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: IRLAB
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Germany, Poland, Spain
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lethargy|Parkinson's Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07461220 |
LIFT-PD | P2 |
Recruiting |
Parkinson's Disease|Lethargy |
2027-05-01 |
12% |
2026-03-11 |
Primary Endpoints|Treatments |
2025-523612-37-00 |
IRL757C003 | P1 |
Not yet recruiting |
Parkinson's Disease |
2027-02-28 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/10/2023 |
News Article |
IRLAB to present at Redeye Neurology Theme Event on October 11, 2023 |
|
02/13/2023 |
News Article |
IRLAB Updates on Portfolio Development Milestones |
|
01/12/2023 |
News Article |
IRLAB Nominates IRL1117 As Drug Candidate from The P003 Project to Develop a Novel Treatment for Parkinson's Disease |
|
01/06/2023 |
News Article |
IRLAB to Present at the 6th Neuroscience Innovation Forum in San Francisco on January 8, 2023 |